4.6 Article

A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression

Journal

JOURNAL OF NEUROSURGERY
Volume 116, Issue 2, Pages 315-322

Publisher

AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/2011.10.JNS102122

Keywords

deep brain stimulation; depression; mood disorder; psychiatry; cingulate gyrus; subgenual cingulate

Funding

  1. Canadian Academy of Geriatric Psychiatry
  2. CIHR
  3. Department of Psychiatry-University Health Network
  4. Eli Lilly Canada Inc.
  5. Michael J. Fox Foundation for Parkinson's Research
  6. St. Jude Medical
  7. NARSAD
  8. AstraZeneca
  9. Biovail
  10. Eli Lilly
  11. GlaxoSmithKline
  12. Janssen-Ortho
  13. Lundbeck
  14. Pfizer
  15. Servier
  16. University of British Columbia) from Advanced Neuromodulation Systems Inc.
  17. BrainCells Inc.
  18. Canadian Institutes of Health Research
  19. Canadian Psychiatric Research Foundation
  20. Litebook Company Ltd.
  21. Mathematics of Information Technology and Advanced Computing Systems
  22. Michael Smith Foundation for Health Research
  23. UBC Institute of Mental Health/Coast Capital Savings
  24. Advanced Neuromodulation Systems Inc./St. Jude Medical
  25. B. C. Health Research Foundation
  26. Cyberonics Inc.
  27. Medical Research Council of Canada
  28. Medtronic of Canada Ltd.
  29. QLT Photo Therapeutics Inc.
  30. Titan Pharmaceuticals
  31. Vancouver Coastal Health Authority
  32. Vancouver General Hospital/University of B.C. Hospital Foundation

Ask authors/readers for more resources

Object. Deep brain stimulation (DBS) has been recently investigated as a treatment for major depression. One of the proposed targets for this application is the subcallosal cingulate gyms (SCG). To date, promising results after SCG DBS have been reported by a single center. In the present study the authors investigated whether these findings may be replicated at different institutions. They conducted a 3-center prospective open-label trial of SCG DBS for 12 months in patients with treatment-resistant depression. Methods. Twenty-one patients underwent implantation of bilateral SCG electrodes. The authors examined the reduction in Hamilton Rating Scale for Depression (HRSD-17) score from baseline (RESP50). Results. Patients treated with SCG DBS had an RESP50 of 57% at 1 month, 48% at 6 months, and 29% at 12 months. The response rate after 12 months of DBS, however, increased to 62% when defined as a reduction in the baseline HRSD-17 of 40% or more. Reductions in depressive symptomatology were associated with amelioration in disease severity in patients who responded to surgery. Conclusions. Overall, findings from this study corroborate the results of previous reports showing that outcome of SCG DBS may be replicated across centers. (DOI: 10.3171/2011.10.JNS102122)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available